SCHEMBL700113

SCHEMBL700113

O=C(NO)c1ccc(Nc2ncnc(-c3cnc4ccccn34)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 8/20 0.48
IGF1R P08069 2/20 0.48
HDAC3 O15379 4/20 0.45
HDAC1 Q13547 4/20 0.45
CDK7 P50613 3/20 0.45
CDK9 P50750 3/20 0.45
RPS6KB1 P23443 1/20 0.45
FLT3 P36888 1/20 0.45
JAK3 P52333 1/20 0.45
BTK Q06187 1/20 0.45
CAMK2D Q13557 1/20 0.45
HDAC6 Q9UBN7 4/20 0.44
PKM P14618 4/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
CDK1 P06493 2/20 0.44
CDK4 P11802 2/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699645 0.85 CDK2 (0.67) CDK2IGF1RHDAC3HDAC1JAK3
SCHEMBL699361 0.85 HDAC1 (0.59) CDK2IGF1RHDAC3HDAC1NPC1
SCHEMBL699813 0.83 CDK2 (0.50) CDK2IGF1RHDAC3HDAC1CDK7
SCHEMBL699910 0.83 CDK2 (0.52) CDK2IGF1RHDAC3HDAC1CDK7
SCHEMBL3679760 0.79 PKM (0.74) CDK2RPS6KB1FLT3HDAC6PKM
SCHEMBL13984939 0.77 PKM (0.48) HDAC3HDAC1FLT3HDAC6PKM
SCHEMBL13984934 0.76 MEN1 (0.49) CDK2RPS6KB1FLT3HDAC6PKM
SCHEMBL4210254 0.76 PKM (0.47) CDK2IGF1RHDAC3HDAC1CDK7
SCHEMBL702011 0.76 IKBKE (0.45) CDK2IGF1RHDAC3HDAC1FLT3
SCHEMBL699041 0.74 CDK2 (0.68) CDK2IGF1RHDAC1CAMK2DPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US claimed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 CDK2 16/4885IGF1R 1719/4885HDAC3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.